Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,162 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Atherosclerosis, Coronary Clear all

Conditions: Healthy Volunteers
Interventions: Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stress Disorders, Post-Traumatic
Interventions: Cognitive behavioral therapy (CBT), Educational session and treatment as usual; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: New York, New York • Queens, New York

Conditions: Coronary Artery Disease
Interventions: iodixanol; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Decision-making tool for coronary artery disease treatment; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more

Conditions: Coronary Disease
Interventions: CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Rebecca Torguson; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Non-Obstructive Coronary Atherosclerosis
Interventions: Coronary computed tomography angiography (CCTA), Isovue, Nitroglycerin, Metoprolol; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 125 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease, Acute Coronary Syndrome
Interventions: Fractional Flow Reserve; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Huntsville, Alabama • Orlando, Florida • Decatur, Georgia + 1 more

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: Saint Michael's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Atrial Fibrillation, Arrhythmia, Stroke, Cardiovascular
Interventions: The Lifestar Act III; Device
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Hyperlipidemia, Hypercholesterolemia, Coronary Heart Disease, Cardiovascular Disease
Interventions: Simvastatin; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Coronary Syndrome, Chest Pain
Interventions: Observation unit care, coupled with cardiac MRI; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stable Angina
Interventions: T89(Dantonic); Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Stent Thrombosis, Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Coronary Artery Disease
Interventions: Emerge™ 1.20 mm PTCA Dilatation Catheter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Refractory Angina
Interventions: Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry; Device · Other
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 72
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more

Conditions: Myocardial Infarction, Stable Angina, Coronary Artery Disease
Interventions: Early appointment (within 10 days), Routine referral (at 5 weeks); Behavioral · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
Interventions: Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up; Behavioral
Lead sponsor: Precision Health Equity Initiative; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Coronary Stenosis, Coronary Artery Disease
Interventions: IoNIR Ridaforolimus-Eluting Coronary Stent System; Device
Lead sponsor: Medinol Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roslyn, New York

Conditions: Coronary Artery Disease
Interventions: Cleerly Labs and Cleerly ISCHEMIA; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Mobile, Alabama • Huntington Park, California • San Diego, California + 18 more

Conditions: Peripheral Arterial Disease
Interventions: Ischemic preconditioning, Control; Other
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Patient-Reported Preferences Affecting Revascularization Decisions

The PEARL 8.0 Post-Approval Study

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction

PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease

PRESSUREwire Study

Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)

Prevention of Serious Adverse Events Following Angiography

Cholesterol and Pharmacogenetic Study

Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

Stent Thrombosis In Acute Coronary Syndromes

Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Readiness for Behavior Change After a Heart Attack

The RISC Registry--Risk Informed Screening Registry

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery